drugset / Trial / NCT05944627

Evaluate Safety and Explore Efficacy of FURESTEM-OA Kit Inj. in Patients With Knee Osteoarthritis

NCT05944627 ↗

Phase 1/2 Unknown 68 enrolled Kang Stem Biotech Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

A Single, Dose Escalation, Optimal Dose Finding Phase I/IIa Clinical Trial to Evaluate Safety and Explore Efficacy of the Single Treatment of FURESTEM-OA Kit Inj. in Patients with Knee Osteoarthritis

Timeline

Start
2023-07-06
Primary completion
2024-03-31
Completion
2026-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject FURESTEM-OA Inj. Unknown — Other
Background CAM Inj. Unknown — Other

Indications